AstraZeneca Seeks Partners in Pediatric Asthma & Allergy, Metabolic Disorders, Chronic Kidney Disease, Hyperkalemia, and Community-based Chronic Disease Management

Recruit ecological partners related to pediatric asthma, allergy testing, home treatment, and prevention, including but not limited to:

· Nebulizer (including home use)

· Equipment for pulmonary function testing, airway inflammation index testing, and allergen testing

· Intelligent Devices for Home Asthma Monitoring and Acute Attack Early Warning Solutions (Such as Oxygen Concentrators and Other Related Respiratory Equipment)

2. Partners meet the following criteria:

- The product is mature and has been launched;

- With experience in online and offline promotion outside the hospital, and the ability to expand hospital channels;

- The following qualifications are preferred: the ability to achieve interoperability of patient management both inside and outside the hospital, the capability to provide solutions that promote the implementation of home nebulization concepts, and a strong willingness to cooperate.

3. Project Background:

The current situation of childhood asthma in China is severe, with a total prevalence rate of 3.02% among children aged 0-14, and it has shown a significant increase over the past 10 years. Asthma has become one of the common chronic respiratory diseases in children.

AstraZeneca Always Focuses on Enhancing the Standardized Diagnosis and Treatment Capabilities for Children's Cough, Asthma, and Respiratory Immune Diseases, as Well as Comprehensive Disease Management. It Actively Supports Projects Such as "Ten Thousand Nebulization Rooms" and "Standardized Pediatric Asthma Clinics," and Engages in In-Depth Collaboration with Thousands of Medical Institutions Across China to Fully Ensure the Safety and Health of Children. Under the Current Medical Environment and Disease Diagnosis and Treatment Conditions, AstraZeneca Drives the Upgrade of Its Business Model, Innovates the Hospital Outpatient and Emergency Nebulization Model, and Promotes the Iteration of Service Models Extending from Inside Hospitals to Outside Hospitals, Placing Greater Emphasis on Long-Term Management of Home Nebulization and Asthma for Children. By Upgrading the Pediatric Intelligent Nebulization Center Through Ecosystem Co-Building, Efficient Diagnosis Can Be Achieved Using Convenient and Humanized Detection Technologies, Providing Standardized Treatment Solutions That Extend From Hospitals to Homes, and Managing the Entire Process Through Intelligent Management Service Software: Smart Medication Reminders, Disease Education, and Timely Warnings for Patients at Risk of Acute Exacerbations, Ultimately Achieving Effective Symptom Control and Improving the Prognosis of Affected Children. This Further Optimizes the Allocation of Medical Resources and Brings Benefits to Patients.

4. Requirement Deadline:

January 31, 2024

2. Partners meet the following criteria:

For metabolic diseases: including diabetes and related complications, hyperlipidemia, obesity, hyperuricemia, osteoporosis, etc., we are recruiting partners in the following areas:

- For metabolic diseases and complicationsScreening and Diagnostic Technologies and Instruments；

- For metabolic diseases and complicationsTreatment technologies and instruments;

- For metabolic diseasesMedical foods for adjuvant therapy;

- Utilizing technologies such as the Internet, the Internet of Things, and artificial intelligence to serve metabolic diseasesThe whole process of prevention, screening, diagnosis, treatment, and health management, the entire life cycle of patientsInnovative Diagnosis and Treatment Model, including digital therapeutics;

- We hope that the product technology of relevant partners will be mature.Already approved for marketing or clinical application。

3. Project Background:

MMC (National Standardized Metabolic Disease Management Center) was initiated by Professor Ning Guang, an academician of the Chinese Academy of Engineering, and is managed by the National Clinical Research Center for Metabolic Diseases / Shanghai Institute of Endocrinology and Metabolic Diseases. It promotes the standardized management system for metabolic diseases across China. MMC pioneers a new model for the diagnosis and management of metabolic diseases, positioning endocrinology at the forefront of chronic metabolic disease management. As of September 2023, MMC has been established nationwide in China.Over 1,800 hospitalsJoin MMC, whereNearly 1,300 physical centersCarry out diabetes patient management work. Covering 31 provinces and municipalities across China and the Macao Special Administrative Region, managementNearly 1.5 millionDiabetic patients.

● Expert Resources:Led by Academician Ning Guang and Director Wei Qing Wang, an advisory group composed of endocrinology experts from across China.

● Research Cooperation：Yangtze River Delta Health Research Institute of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, and China Endocrinology and Metabolism Diseases Specialty Alliance.

● Collaboration Network:After evaluation and verification by the expert group, there will be an opportunity to enter the National Standardized Metabolic Disease Management Platform (MMC) for collaborative cooperation.

● Metabolic Disease Industrial Park (MCampus):Initiated by Academician Ning Guang and based on MMC, MCampus is a strategic collaboration among Wuxi High-Tech Zone, AstraZeneca, and Zhizhong Medical. As an open ecosystem for the integrated development of "clinical practice + industry," it establishes an innovative model where "clinical needs drive industrial development, and industrial development serves clinical diagnosis and treatment." This creates a life sciences innovation cluster centered on the field of metabolic disease diagnosis and treatment, ultimately benefiting innovative companies in the metabolic treatment sector and a wide range of patients with metabolic diseases.

4. Requirement Deadline:

March 2024